News

Novo Nordisk is set to share groundbreaking data from its HIBISCUS phase 2 trial at the 66th Annual Meeting of the American Society of Hematology (ASH) in San Diego. This …

AB SCIENCE USA, LLC announced that it has received a notice of allowance from the European Patent Office for a patent covering the use of masitinib, an oral therapy in …

KINDPharmaceutical, a biotech company, announced that the FDA has granted Orphan Drug Designation to their drug AND017 for treating sickle cell disease. AND017 is being developed by KIND to treat …

The Phase 3 RISE UP trial has marked a significant step forward in addressing sickle cell disease (SCD). @Agios Pharmaceuticals has completed enrollment for this pivotal study. The trial is …

Zydus Group and Indian Council of Medical Research (ICMR) have announced a collaboration to begin testing a new medicine for sickle cell disease. They’re initiating a Phase 2 trial of …

In a strategic move within the hematology field, French pharmaceutical company MITEM Pharma has successfully acquired the global rights to Desferal (deferoxamine) from Novartis. Desferal, an essential medicine listed by …

The phase III COMMANDS trial has revealed a massive development in treating myelodysplastic syndromes (MDS). According to the primary analysis, Luspatercept, developed by Acceleron Pharma, demonstrated superior efficacy to epoetin …

Agios Pharmaceuticals has reached a significant milestone in the development of their new myelodysplastic syndrome (MDS) treatment, Tebapivat, with the FDA’s recent designation of the drug as an ‘orphan drug’. …

Novo Nordisk has received Subject Expert Committee (SEC) approval from India’s Central Drug Standard Control Organization (CDSCO) to conduct Phase III clinical trials of etavopivat in the treatment of sickle …